Celltrion clears its own 500 billion won profit target by 2% on a 34% operating margin
Celltrion reported preliminary third-quarter operating profit of 510 billion won, up 69.2% from a year earlier, on revenue of 1.5 trillion won. It is the third straight quarter above the company's own target, and Celltrion credits next-generation biosimilars and lower costs.
The Investor · Invest desk
Three key figures. Third-quarter operating profit was 510 billion won, up 69.2% from a year earlier. Revenue was 1.5 trillion won, up 45.8%. Operating margin rose 4.7 percentage points to 34%.
| Figure | Value | Note | Claim |
|---|---|---|---|
| Third-quarter operating profit | 510 billion won | up 69.2% from a year earlier | 1 |
| Third-quarter revenue | 1.5 trillion won | up 45.8% from a year earlier | 2 |
| Operating margin change | 4.7 percentage points | margin now 34% | 3 |
What happened
- Operating margin widened 4.7 percentage points to 34% while revenue grew 45.8%, so profit outran sales.
- Omlyclo is sold in 26 European countries and held more than 90% of the market in Spain as of July, according to Seoul Economic Daily.
- In the US in August, Steqeyma held 15% and Yuflyma 11%, while the older Truxima and Inflectra held 39% and 31%.
- Omlyclo launched in the US in October as the first biosimilar of its kind there, and Celltrion projects it will contribute to fourth-quarter earnings.
Why it matters
- Who's exposed exposure Celltrion expects more than 98% of the Danish market by year-end on the strength of one national tender win, so that share is only as durable as one tender award.
- What's now possible capability Celltrion says the direct-sales network built around its established products increasingly supports newer biosimilars, so each new launch starts with a sales channel that already exists.
- What it limits constraint Management has tied its fourth-quarter and full-year targets to two named drivers, the US launch of Omlyclo and increased supply in Europe, so a shortfall in either goes straight to the target.
Next story · Invest · Oct 8
Europe lifts Korea's biopharma exports to a record $6.6 billionConfirmed2 publishers
Working back from the reported growth rates, Celltrion earned about 301 billion won a year earlier on revenue of about 1.03 trillion won [16][17]. That is a margin of roughly 29.3% [19], consistent with the 4.7 point gain to 34% [3]. Revenue added about 471 billion won and operating profit about 209 billion won, so each extra won of sales carried about 44 won of operating profit [18] (a rough figure, since the reported 1.5 trillion won is rounded).
Celltrion credits a growing share of higher-margin next-generation biosimilars and streamlined production [5]. An incremental margin of 44% against a 34% average fits a mix story, because the new revenue is more profitable than the old. It fits fixed-cost leverage just as well, and the reports do not split the 4.7 points between mix, cost and volume. We think mix is the larger part, though the evidence is only the ordering in Seoul Economic Daily's account. It lists the larger share of higher-margin follow-on products first and says efficiency and a better cost structure also supported profitability [11].
The beat is small. The third-quarter target was more than 500 billion won, and 510 billion won clears it by 2% [14], after targets of 300 billion won for the first quarter and 400 billion won for the second [4]. "We have exceeded our target every quarter through the third quarter, proving the profit growth plan we laid out at the start of the year," a Celltrion official said [9]. Three straight beats fit two readings: targets set to be cleared, or a business landing close to plan. The first- and second-quarter actuals would separate them.
The 34% margin also predates the product the company expects to add to fourth-quarter earnings. Omlyclo launched in the US in October [7], after the July-to-September quarter had closed [15], and its place on Optum's private formulary brings reimbursement in the fourth quarter [8]. Celltrion said it expects growth momentum to continue [21].
The fourth quarter is still a weak test of the margin thesis. European tenders and supply schedules concentrate in the second half, with year-end inventory demand expected to rise, according to Seoul Economic Daily [20], so the quarter sits in the same stretch as the one just reported. A first-quarter margin next year back near the 29.3% of a year earlier [19] would say the third quarter owed more to timing than to mix.
What to watch
- Celltrion's final third-quarter consolidated results against the preliminary 510 billion won and 34% margin.
- Fourth-quarter operating profit and margin once Optum reimbursement for Omlyclo begins, and whether Denmark reaches its expected share of more than 98% by year-end.
- Celltrion's first-quarter margin next year, the cleaner test of product mix against second-half tender timing.
Information, not investment advice. This story is general information about companies and markets, drawn from cited reporting. It is not a recommendation to buy, sell or hold any security; check the cited sources before acting.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence62
- Adoption58
- Hype gap+12
- Incentives50
- Confidence68
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
Celltrion reported preliminary consolidated third-quarter operating profit of 510 billion won, up 69.2% from a year earlier.
- [2]
Celltrion reported third-quarter consolidated revenue of 1.5 trillion won, up 45.8% from a year earlier.
- [3]
Celltrion's operating margin rose 4.7 percentage points year on year to 34%.
- [4]
In its business outlook released earlier this year, Celltrion set quarterly operating profit targets of 300 billion won for the first quarter, 400 billion won for the second and more than 500 billion won for the third.
- [5]
Celltrion said it exceeded each target on an improving product mix, with higher-margin next-generation biosimilars accounting for a growing share of sales, alongside efforts to streamline production and lower costs.
- [6]
Celltrion noted that its direct-sales infrastructure, built around established products, has increasingly supported the commercial rollout of newer biosimilars.
- [7]
Omlyclo launched in the US in October as the first biosimilar of its kind in the market, and is projected to contribute to Celltrion's fourth-quarter earnings.
- [8]
On its US launch Omlyclo was listed as a preferred drug on the private insurance formulary of Optum, one of the three largest US pharmacy benefit managers; reimbursement takes effect in the fourth quarter.
- [9]
"We have exceeded our target every quarter through the third quarter, proving the profit growth plan we laid out at the start of the year," a Celltrion official said.
- [10]
The third quarter covers the July-to-September period.
- [11]
Seoul Economic Daily wrote that the improvement reflects a larger share of revenue from higher-margin follow-on biosimilars, and that more efficient production and a better cost structure also supported profitability.
- [12]
Omlyclo is sold in 26 European countries and held a market share of more than 90% in Spain as of July.
- [13]
In the US in August, Steqeyma held a 15% market share, Yuflyma 11%, Truxima 39% and Inflectra 31%.
- [14]
The 510 billion won result clears the third-quarter target of more than 500 billion won by about 2%.
- [15]
Omlyclo's US launch in October came after the July-to-September quarter closed, so the third-quarter results contain no US launch sales of it.
- [16]
Third-quarter operating profit a year earlier was about 301 billion won.
- [17]
Third-quarter revenue a year earlier was about 1.03 trillion won.
- [18]
Incremental operating margin on the year's added revenue was about 44%: about 209 billion won of added operating profit on about 471 billion won of added revenue.
- [19]
The year-earlier third-quarter operating margin was about 29.3%.
- [20]
In Europe, tenders and supply schedules in major markets are concentrated in the second half, and year-end inventory demand is expected to rise.
- [21]
Celltrion said it expects its growth momentum to continue in the fourth quarter on the back of expanding sales and a more profitable product mix.
- [22]
Celltrion named the US launch of Omlyclo and increased supply in Europe as growth drivers for meeting its fourth-quarter and full-year business targets.
- [23]
In Denmark, Celltrion expects Omlyclo to reach a share of more than 98% by the end of the year on the back of a national tender win.
Sources
2 independent publishers whose own reporting we read for this story.
- en.sedaily.comCelltrion Posts Record Quarterly Profit on High-Margin Biosimilars
2 articles · October 12, 2026
- koreaherald.comCelltrion posts first W500b quarterly operating profit
1 article · October 11, 2026
Topics and entities
Topics
- Biosimilars
- Pharmaceutical earnings
- Pharmacy benefit formularies